By Nuala Moran Staff Writer LONDON – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has had another Glybera moment, turning down the rare disease drug Raxone (idebenone) by a narrow majority, despite the rapporteurs on an expert committee recommending approval of the drug, which treats a hereditary cause of blindness
Heptares said its stabilized GPCRs preserve all biologically relevant epitopes and allow a diverse panel of functional antibodies to be obtained when they are used as an antigen for in vivo immunization.
By Nuala Moran | BioWorld International | Wednesday, January 9, 2013
Heptares said its stabilized GPCRs preserve all biologically relevant epitopes and allow a diverse panel of functional antibodies to be obtained when they are used as an antigen for in vivo immunization.
By Nuala Moran | BioWorld Today | Tuesday, January 8, 2013
The rights issue already is guaranteed, with the French public fund Fonds Stratégique d'Investissement agreeing to subscribe up to €25 million, while Groupe Grimaud and Unigrains (one of Groupe Grimaud's long-term shareholders) have said they will take up €5 million, and two banks have committed to underwrite €10 million under standard terms.
By Nuala Moran | BioWorld International | Wednesday, December 19, 2012
Upon achievement of certain preclinical, clinical, regulatory and commercial goals, Janssen would make future milestone payments of up to $300 million per product.
By Nuala Moran | BioWorld International | Wednesday, December 19, 2012
Upon achievement of certain preclinical, clinical, regulatory and commercial goals, Janssen would make future milestone payments of up to $300 million per product.
By Nuala Moran | BioWorld Today | Tuesday, December 18, 2012
The rights issue already is guaranteed, with the French public fund Fonds Stratégique d'Investissement agreeing to subscribe up to €25 million, while Groupe Grimaud and Unigrains (one of Groupe Grimaud's long-term shareholders) have said they will take up €5 million, and two banks have committed to underwrite €10 million under standard terms.
By Nuala Moran | BioWorld Today | Tuesday, December 18, 2012
Upon achievement of certain preclinical, clinical, regulatory and commercial goals, Janssen would make future milestone payments of up to $300 million per product.
By Nuala Moran | BioWorld Today | Monday, December 17, 2012
But given median overall survival was not reached in 22.2 months of follow-up in the Phase III trial, and with no limiting toxic side effects seen to date, patients could be taking Zytiga for two years or longer.
By Nuala Moran | BioWorld Today | Friday, December 14, 2012
By Nuala Moran Staff Writer LONDON – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has had another Glybera moment, turning down the rare disease drug Raxone (idebenone) by a narrow majority, despite the rapporteurs on an expert committee recommending approval of the drug, which treats a hereditary cause of blindness